What is your business idea, what problem do you want to solve?
“Sprint Bioscience’s goal is to cure more people who are diagnosed with cancer. The large drug companies are looking for innovations to broaden their portfolios of drug projects. They do this by buying innovation from small, creative companies such as Sprint Bioscience,” says Erik Kinnman, Sprint Bioscience CEO.
“We identify, start and develop drug projects in the pre-clinical phase. The goal is to manage these projects, together with a licensee, all the way to a finished product. Our business idea is to develop drug candidates that can be new, innovative treatments by tying up as little capital as possible.
Where are you now?
“Now we are about 30 employees where most work in our research projects such as drug chemists, biochemists and cell biologists. We are a public company, listed on the Nasdaq First North Premier Growth Market and have so far signed global licensing agreements for three pharmaceutical projects to a potential value of $ 470 million in interim payments and additional royalties on sales”, says Erik Kinnman.
“Our model differs from how other smaller biotech firms manage and finance drug development. We start new, innovative drug projects and license them in the pre-clinical phase. This allows us to review a project’s commercial value at an early stage, and thereby minimize risk in our project portfolio. Today, we’re known in the international drug industry for delivering projects of high quality and high medical relevance.
What are you plans for the future?
“We have adapted our premises to our specific needs. Our modern offices and new laboratories are adapted to our way of working and support our creativity, and there are opportunities for future expansion. We will continue to recruit both drug developers and other functions within the company”, says Erik Kinnman.
Why are you based in Flemingsberg?
“In Flemingsberg, there is an opportunity for us to grow and offer a good working environment for our employees. Here are the benefits of proximity to research at Karolinska Institutet and clinical research at Karolinska University Hospital. We are also attracted by the fact that the area represents innovation and looks forward with excitement to the upcoming development and that we, together with the other Life Science companies in the area, will be an important part of the new Flemingsberg”.